NOVEL BIOMARKER FOR ENDOMETRIOSIS
SYNG Pharma has discovered a biomarker for endometriosis, a protein which has a role in allowing endometrial cells to spread outside the uterus. SYNG Pharma has developed a proprietary test which has potential to become the first line test for endometriosis. The test is currently in clinical validation stage.
We hope to reach commercialization stage in Q2 of 2018
NON-HORMONAL THERAPY FOR ENDOMETRIOSIS
SYNG Pharma’s current lead candidate (SP012) is a molecule which specifically targets this biomarker and inhibits the proliferation of endometriotic lesions. SP012 has potential to become the standard of care as it may have disease modifying properties and deliver benefits without affecting reproductive outcomes.
SP011 is awaiting completion of IND enabling studies. We hope to initiate Phase 1 clinical studies by Q3 of 2018.
SYNG Pharma has granted patents and pending patent applications for composition of matter and methods. SYNG Pharma is pursuing an intellectual property protection strategy through various patent filings related to endometriosis and other applications in stomach, prostate, uterine and ovarian cancers.